Genmab


R&D pipeline progressing well

20/11/20 -"Better than expected performance of Tepezza and the upcoming launch of Amivantamab should bolster Genmab’s top line in the near term. Moreover, encouraging clinical data for pipeline assets, ..."

Pages
49
Language
English
Published on
20/11/20
You may also be interested by these reports :
03/12/20
Despite the generic erosion of Somatuline, Ipsen is targeting +2-5% sales growth p.a. until FY24, driven by the maximisation of the value of ...

02/12/20
Recently, there has been pertinent share price performance divergence between Novartis and Roche. While, for a long time, Novartis had the upper ...

27/11/20
After being range-bound for the most part of 2019, UCB (Add, Belgium) gained momentum in October 2019 when the company made an acquisition in the ...

26/11/20
Novartis unveiled promising performance targets at its 2020 CMD. Besides striving for healthy top-line growth – driven by diverse innovations, the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO